市場調查報告書

全球降壓藥市場:2019-2025

Anti-Hypertensive Drugs Market 2019-2025

出版商 Orion Market Research Pvt Ltd 商品編碼 949429
出版日期 內容資訊 英文
商品交期: 2-3個工作天內
價格
全球降壓藥市場:2019-2025 Anti-Hypertensive Drugs Market 2019-2025
出版日期: 2020年05月21日內容資訊: 英文
簡介

預計在預測期內,全球抗高血壓藥市場將以穩定的複合年增長率增長。推動市場增長的主要因素是全球範圍內易患高血壓等疾病的老年人口的增加。在預測期內,亞太地區估計將在全球降壓藥市場中顯示出顯著增長。該地區老年人口的增長正在推動市場增長。此外,醫療保健基礎設施的改善進一步推動了區域市場的增長。此外,亞太地區的公司正在將新藥投放市場,這將進一步加速該地區市場的增長。

本報告調查並分析了全球降壓藥市場,市場概況,影響市場增長的因素,市場規模和預測,按細分市場進行的分析,按地區/國家進行的市場分析,競爭情況等。提供有關的系統信息。

內容

第1章報告概述

第2章市場概述和討論

  • 調查範圍
  • 分析師見解和當前市場趨勢
  • 規則與規定

第3章競爭情況

  • 公司份額分析
  • 主要策略分析
  • 主要公司分析
    • 輝瑞公司
    • 強生公司
    • 賽諾菲SA
    • 勃林格殷格翰國際有限公司
    • 阿斯利康PLC

第4章市場決定因素

  • 主持人
  • 抑制因子
  • 機會

第5章市場細分

  • 全球抗高血壓藥物市場(按藥物類別)
    • 塞秦類利尿劑
    • 鈣通道阻滯劑
    • ACE抑製劑
    • 血管緊張素II受體阻滯劑(ARBS)
    • Beta阻滯劑(Beta阻滯劑)
    • 其他

第6章區域分析

  • 北美
    • 美國
    • 加拿大
  • 歐洲
    • 英國
    • 德國
    • 意大利
    • 西班牙
    • 法國
    • 其他歐洲
  • 亞太地區
    • 中國
    • 印度
    • 日本
    • 其他亞太地區
  • 其他地區

第7章公司簡介

  • AstraZeneca PLC
  • Bayer AG
  • Boehringer Ingelheim International GmbH
  • Daiichi Sankyo Co., Ltd.
  • Johnson & Johnson Services, Inc.
  • Lupin Ltd.
  • Merck KGaA
  • Noden Pharma DAC
  • Novartis International AG
  • Pfizer Inc.
  • Ranbaxy LaboratoriesLtd.
  • Renata Ltd.
  • Sanofi S.A.
  • Sun Pharmaceuticals LLC
  • 武田藥品工業
  • Teva Pharmaceutical Industries Ltd.
  • Unichem Laboratories Ltd.
  • United Therapeutics Corp.
目錄
Product Code: OMR2021748

Anti-Hypertensive Drugs Market Size, Share & Trends Analysis Report by Drug Class (Thiazide Diuretics, Calcium Channel Blockers, ACE Inhibitors, Angiotensin II Receptor Antagonists (ARBs), Beta-Blockers, and Others), and Forecast 2020-2026

The global anti-hypertensive drugsmarket is anticipated to grow at a steady CAGR during the forecast period. Anti-hypertensive drugsare used in the treatment of hypertension.There are various classes of antihypertensive drugs available in the market. Allanti-hypertensive drugswork in differentways to lower blood pressure. While some of the anti-hypertensive drugs work by removing extra fluid and salt from the body, others relax and widen the blood vessels or slow the heartbeat as per their action.The major factor contributing to the growth of the market include increasing geriatric population across the globe as they are more prone to the disease such as hypertension.

The global anti-hypertensive drugs market is segmented on the basis of the drug class. Based on the drug class, the market is sub-segmented into and thiazide diuretics, calcium channel blockers, ACE inhibitors, angiotensin II receptor antagonists (ARBs), beta-blockers, and others such as renin inhibitors. Thiazide diuretics are estimated to contribute a prominent share in the market.

Geographically, the study of the global anti-hypertensive drugs market report covers the analysis of four major regions including North America (the US and Canada), Europe (UK, Germany, Italy, Spain, France, and Rest of Europe), Asia-Pacific (China, Japan, India, and the Rest of Asia-Pacific), and the Rest of the World. Asia-Pacific is estimated to exhibit a significant growth rate in the global anti-hypertensive drugs market during the forecast period. The increasing geriatric population in the region drives the growth of the market. In addition, improving healthcare infrastructure further gives a boost to the regional growth of the market.

Moreover, the players in the Asia-Pacific region are bringing new drugs to the market which further gives a boost to the regional growth of the market.For instance, in May 2019, Daiichi Sankyo Co.Ltd. announced the launch of MINNEBRO Tablets 1.25 mg, 2.5 mg and 5 mg (generic name: esaxerenone; hereafter, the drug) in Japan. Further, the study of the report covers the analysis of various players. Some of the players operating in the market include Pfizer Inc., Johnson & Johnson Services, Inc., Sanofi SA, Boehringer Ingelheim International GmbH, AstraZeneca PLC, Daiichi Sankyo Co.Ltd., Teva Pharmaceutical Industries Ltd., and others.

Research Methodology

The market study of the global anti-hypertensive drugsmarket is incorporated by extensive primary and secondary research conducted by the research team at OMR. Secondary research has been conducted to refine the available data to breakdown the market in various segments, derive total market size, market forecast, and growth rate. Different approaches have been worked on to derive the market value and market growth rate. Our team collects facts and data related to the market from different geography to provide a better regional outlook. In the report, the country-level analysis is provided by analyzing various regional players, regional tax laws and policies, consumer behavior, and macro-economic factors. Numbers extracted from secondary research have been authenticated by conducting proper primary research. It includes tracking down key people from the industry and interviewing them to validate the data. This enables our analyst to derive the closest possible figures without any major deviations in the actual number. Our analysts try to contact as many executives, managers, key opinion leaders, and industry experts. Primary research brings authenticity to our reports.

Secondary Sources Include:

  • Financial reports of companies involved in the market.
  • Whitepapers, research-papers, and news blogs.
  • Company websites and their product catalog.

The report is intended for the drug manufacturers,pharmaceutical industry, active pharmaceutical ingredient manufacturers,hospitals & clinics, government organizations, regulatory bodies, and other market participantsfor overall market analysis and competitive analysis.The report provides an in-depth analysis of market size, products offered by the company, and future market opportunities. The report will serve as a source for a 360-degree analysis of the market thoroughly delivering insights into the market for making better business decisions.

Market Segmentation

1. GlobalAnti-hypertensiveDrugsMarket Research and Analysis by Drug Class

The Report Covers:

  • Comprehensive research methodology of the global anti-hypertensive drugsmarket.
  • This report also includes a detailed and extensive market overview with key analyst insights.
  • An exhaustive analysis of macro and micro factors influencing the market guided by key recommendations.
  • Analysis of regional regulations and other government policies impacting the global anti-hypertensive drugsmarket.
  • Insights about market determinants which are stimulating the global anti-hypertensive drugsmarket.
  • Detailed and extensive market segments with regional distribution of forecasted revenues.
  • Extensive profiles and recent developments of market players.

Table of Contents

1. Report Summary

  • 1.1. Research Methods and Tools
  • 1.2. Market Breakdown
    • 1.2.1. By Segments
    • 1.2.2. By Geography

2. Market Overview and Insights

  • 2.1. Scope of the Report
  • 2.2. Analyst Insight & Current Market Trends
    • 2.2.1. Key Findings
    • 2.2.2. Recommendations
    • 2.2.3. Conclusion
  • 2.3. Rules & Regulations

3. Competitive Landscape

  • 3.1. Competitive Dashboard
  • 3.2. Key Strategy Analysis
  • 3.3. Key Company Analysis
    • 3.3.1. Pfizer Inc.
      • 3.3.1.1. Overview
      • 3.3.1.2. Financial Analysis
      • 3.3.1.3. SWOT Analysis
      • 3.3.1.4. Recent Developments
    • 3.3.2. Johnson & Johnson Services, Inc.
      • 3.3.2.1. Overview
      • 3.3.2.2. Financial Analysis
      • 3.3.2.3. SWOT Analysis
      • 3.3.2.4. Recent Developments
    • 3.3.3. Sanofi SA
      • 3.3.3.1. Overview
      • 3.3.3.2. Financial Analysis
      • 3.3.3.3. SWOT Analysis
      • 3.3.3.4. Recent Developments
    • 3.3.4. Boehringer IngelheimInternational GmbH
      • 3.3.4.1. Overview
      • 3.3.4.2. Financial Analysis
      • 3.3.4.3. SWOT Analysis
      • 3.3.4.4. Recent Developments
    • 3.3.5. AstraZeneca PLC
      • 3.3.5.1. Overview
      • 3.3.5.2. Financial Analysis
      • 3.3.5.3. SWOT Analysis
      • 3.3.5.4. Recent Developments

4. Market Determinants

  • 4.1. Motivators
  • 4.2. Restraints
  • 4.3. Opportunities

5. Market Segmentation

  • 5.1. Global Antihypertensive drugsMarket by Drug Class
    • 5.1.1. Thiazide Diuretics
    • 5.1.2. Calcium Channel Blockers
    • 5.1.3. ACE Inhibitors
    • 5.1.4. Angiotensin II Receptor Antagonists (ARBS)
    • 5.1.5. Beta Blockers
    • 5.1.6. Others

6. Regional Analysis

  • 6.1. North America
    • 6.1.1. United States
    • 6.1.2. Canada
  • 6.2. Europe
    • 6.2.1. UK
    • 6.2.2. Germany
    • 6.2.3. Italy
    • 6.2.4. Spain
    • 6.2.5. France
    • 6.2.6. Rest of Europe
  • 6.3. Asia-Pacific
    • 6.3.1. China
    • 6.3.2. India
    • 6.3.3. Japan
    • 6.3.4. Rest of Asia-Pacific
  • 6.4. Rest of the World

7. Company Profiles

  • 7.1. AstraZeneca PLC
  • 7.2. Bayer AG
  • 7.3. Boehringer Ingelheim International GmbH
  • 7.4. Daiichi Sankyo Co., Ltd.
  • 7.5. Johnson & Johnson Services, Inc.
  • 7.6. Lupin Ltd.
  • 7.7. Merck KGaA
  • 7.8. Noden Pharma DAC
  • 7.9. Novartis International AG
  • 7.10. Pfizer Inc.
  • 7.11. Ranbaxy LaboratoriesLtd.
  • 7.12. Renata Ltd.
  • 7.13. Sanofi S.A.
  • 7.14. Sun Pharmaceuticals LLC
  • 7.15. Takeda Pharmaceutical Company Ltd.
  • 7.16. Teva Pharmaceutical Industries Ltd.
  • 7.17. Unichem Laboratories Ltd.
  • 7.18. United Therapeutics Corp.

LIST OF TABLES

  • 1. GLOBAL ANTIHYPERTENSIVE DRUGS MARKET RESEARCH AND ANALYSIS BY DRUG CLASS, 2019-2026 ($ MILLION)
  • 2. GLOBAL THIAZIDE DIURETICS MARKET RESEARCH AND ANALYSIS BY REGION, 2019-2026 ($ MILLION)
  • 3. GLOBAL CALCIUM CHANNEL BLOCKERS MARKET RESEARCH AND ANALYSIS BY REGION, 2019-2026 ($ MILLION)
  • 4. GLOBAL ACE INHIBITORSMARKET RESEARCH AND ANALYSIS BY REGION, 2019-2026 ($ MILLION)
  • 5. GLOBAL ANGIOTENSIN II RECEPTOR ANTAGONISTS (ARBS)MARKET RESEARCH AND ANALYSIS BY REGION, 2019-2026 ($ MILLION)
  • 6. GLOBAL ALPHA BLOCKERS MARKET RESEARCH AND ANALYSIS BY REGION, 2019-2026 ($ MILLION)
  • 7. GLOBAL BETA BLOCKERSMARKET RESEARCH AND ANALYSIS BY REGION, 2019-2026 ($ MILLION)
  • 8. GLOBAL OTHER ANTIHYPERTENSIVE DRUGS MARKET RESEARCH AND ANALYSIS BY REGION, 2019-2026 ($ MILLION)
  • 9. GLOBAL HYPERTENSION MARKET RESEARCH AND ANALYSIS BY GEOGRAPHY, 2019-2026 ($ MILLION)
  • 10. NORTH AMERICAN ANTIHYPERTENSIVE DRUGS MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2019-2026 ($ MILLION)
  • 11. NORTH AMERICAN ANTIHYPERTENSIVE DRUGS MARKET RESEARCH AND ANALYSIS BY DRUG CLASS, 2019-2026 ($ MILLION)
  • 12. EUROPEAN ANTIHYPERTENSIVE DRUGS MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2019-2026 ($ MILLION)
  • 13. EUROPEAN ANTIHYPERTENSIVE DRUGS MARKET RESEARCH AND ANALYSIS BY DRUG CLASS, 2019-2026 ($ MILLION)
  • 14. ASIA-PACIFIC ANTIHYPERTENSIVE DRUGS MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2019-2026 ($ MILLION)
  • 15. ASIA-PACIFIC ANTIHYPERTENSIVE DRUGS MARKET RESEARCH AND ANALYSIS BY DRUG CLASS, 2019-2026 ($ MILLION)
  • 16. REST OF THE WORLD ANTIHYPERTENSIVE DRUGS MARKET RESEARCH AND ANALYSIS BY DRUG CLASS, 2019-2026 ($ MILLION)

LIST OF FIGURES

  • 1. GLOBAL ANTIHYPERTENSIVE DRUGS MARKET SHARE BY DRUG CLASS, 2019 VS 2026(%)
  • 2. GLOBAL ANTIHYPERTENSIVE DRUGS MARKET SHARE BY GEOGRAPHY, 2019 VS 2026(%)
  • 3. US ANTIHYPERTENSIVE DRUGS MARKET SIZE, 2019-2026 ($ MILLION)
  • 4. CANADA ANTIHYPERTENSIVE DRUGS MARKET SIZE, 2019-2026 ($ MILLION)
  • 5. UK ANTIHYPERTENSIVE DRUGS MARKET SIZE, 2019-2026 ($ MILLION)
  • 6. FRANCE ANTIHYPERTENSIVE DRUGS MARKET SIZE, 2019-2026 ($ MILLION)
  • 7. GERMANY ANTIHYPERTENSIVE DRUGS MARKET SIZE, 2019-2026 ($ MILLION)
  • 8. ITALY ANTIHYPERTENSIVE DRUGS MARKET SIZE, 2019-2026 ($ MILLION)
  • 9. SPAIN ANTIHYPERTENSIVE DRUGS MARKET SIZE, 2019-2026 ($ MILLION)
  • 10. ROE ANTIHYPERTENSIVE DRUGS MARKET SIZE, 2019-2026 ($ MILLION)
  • 11. INDIA ANTIHYPERTENSIVE DRUGS MARKET SIZE, 2019-2026 ($ MILLION)
  • 12. CHINA ANTIHYPERTENSIVE DRUGS MARKET SIZE, 2019-2026 ($ MILLION)
  • 13. JAPAN ANTIHYPERTENSIVE DRUGS MARKET SIZE, 2019-2026 ($ MILLION)
  • 14. REST OF ASIA-PACIFIC ANTIHYPERTENSIVE DRUGS MARKET SIZE, 2019-2026 ($ MILLION)
  • 15. REST OF THE WORLD ANTIHYPERTENSIVE DRUGS MARKET SIZE, 2019-2026 ($ MILLION)